A dvances in cancer treatment include the introduction of chemotherapeutic regimens, novel vaccination strategies, and cytokine therapies (1) (2) (3) (4) (5) . Cytokines, including the IFNs, play a critical role in modulating innate and adaptive immune systems (6, 7) . The IFN family is divided into type I and type II IFNs (8) . The type I group contains at least 13 IFN-␣ members, IFN-␤ and IFN-in humans, whereas the type II group is represented by the single member IFN-␥. Type I IFNs modulate the adaptive immune response by increasing MHC class I expression to promote Ag presentation (9) , enhance T cell survival (10) , and stimulate dendritic cell (DC) 3 maturation (7, 11) . In fact, certain type I IFNs have been approved for use in clinical oncology involving hairy cell leukemia, malignant melanoma, and AIDSrelated Kaposi's sarcoma (12) . Notwithstanding these applications, patients undergoing IFN therapy often only have a limited response, and most have adverse effects that include fatigue, fever, and anorexia (13) . Consequently, improved alternative therapies are required for clinical applications.
IFN-1, -2, and -3 (also referred to as IL-29, IL-28a, and IL-28b) were identified as the latest members of the class II cytokine family following computational analysis of the human genomic sequence (14, 15) . Although these new IFNs share limited sequence similarity to type I IFNs, they are expressed by PBMC and DCs following viral infection or stimulation with poly(I:C) (14, 15) , and have been shown to possess antiviral activity similar to type I IFNs (14 -17) . They bind to the common IL-28R (also referred to as CRF2-12, LICR2, and IFN-R1), which associates with IL-10R␤ and serves as a high-affinity binding complex for IFN-s (14 -16) . The heterodimeric receptor mediates JAK1 activation and tyrosine phosphorylation of STAT factors (15, 16) , leading to biological responses similar to those elicited by type I IFNs. The similar mode of action between IFNand type I IFNs suggested that IFN-s might possess antitumor activity.
In a previous study concerning the development of immunization strategies, we demonstrated that use of naked plasmid DNA has considerable potential to modulate humoral and cellular immune responses that protect against cancer and infectious diseases (18 -22) . Specifically, i.v. injection with a large volume of plasmid DNA solution (referred to as the hydrodynamic injection method) can result in preferential gene expression in the liver of rodents (23) (24) (25) (26) . The hydrodynamic method potentially allows for liverselective gene delivery to target metastatic foci.
In this study, we examined the antitumor activity of mouse IFN-with respect to murine tumors. Murine melanoma B16 and colon cancer Colon26 cell lines expressed functional IFN-receptors, and transient transduction using mouse IFN-cDNA into B16 cells enhanced MHC class I expression and the appearance of cell surface Fas (CD95) Ag. Overproduction of IFN-suppressed cell proliferation in vitro by inducing p21
Waf1/Cip1 and dephosphorylated Rb (Ser 780 ), and resulted in increased caspase-3/7 activity. This suggested the induction of apoptotic cell death concomitant with cell cycle arrest. Furthermore, local overproduction of IFNalso inhibited s.c. and metastatic tumor growth in vivo. Therapeutic injection of naked IFN-cDNA by hydrodynamic injection targeted liver metastatic foci of Colon26 cells by increasing the number of NK/NKT cells. Ab-mediated depletion of immune cells supported the notion that the in vivo antitumor activity of IFN-is dependent on a NK cell-mediated tumor destruction pathway. These results demonstrated that local delivery of IFN-induced both tumor apoptosis and NK cell-mediated immunological tumor destruction. Therefore, we propose that use of IFN-might prove a useful adjunctive strategy in the clinical treatment of human malignancies.
Materials and Methods

Animals, cells, and reagents
Male C57BL/6J and BALB/c mice (8 -12 wk old) were purchased from Charles River Japan. All experiments in this study were performed in accordance with the Jichi Medical School Guide for Laboratory Animals.
B16/F0, B16/F10, NIH3T3, L929, and COS7 cells were maintained in DMEM (Invitrogen Life Technologies) with 10% heat-inactivated FCS and supplements (27) . Colon26, EL-4, and P815 cells were grown in RPMI 1640 (Invitrogen Life Technologies) with 10% FCS and supplements. The cultures were kept in a 5% CO 2 and 95% air-humidified atmosphere at 37 o C. Depleting anti-CD4 (clone GK1.5, rat IgG2b) and anti-CD8 (clone 2.43, rat IgG2b) mAb-producing hybridoma cells were obtained from the American Type Culture Collection.
Anti-phospho-Rb (Ser 780 ) (Cell Signaling Technology), anti-mouse p21
Waf1/Cip1 (BD Pharmingen), and anti-actin (sc-1616; Santa Cruz Biotechnology) Abs were used for Western blotting. For the FLAG-tagged IFN-, anti-FLAG M2 mAb (Sigma-Aldrich) was used. For the flow cytometric analysis, PE-conjugated anti-mouse H-2K b mAb, PE-conjugated anti-mouse Fas mAb, PE-conjugated anti-mouse NK1.1 mAb, FITC-conjugated anti-mouse CD3 mAb, and isotype-matched IgG controls were purchased from BD Pharmingen. FITC-conjugated anti-mouse H-2K k mAb was obtained from Miltenyi Biotec.
RT-PCR and mouse IFN-cDNA cloning
Total RNA was extracted from cells using Isogen (Nippon Gene). Two micrograms of total RNA was used for first-strand synthesis using SuperScript III reverse transcriptase (Invitrogen Life Technologies). PCR was then performed using Platinum Pfx polymerase (Invitrogen Life Technologies). The full-length encoding sequence of mouse IFN-(GenBank, NM_001024673) was amplified from bone marrow cell-derived cDNA of BALB/c mice using the following primers: (forward) 5Ј-ATG CTC CTC CTG CTG TTG CCT CT-3Ј and (reverse) 5Ј-TCA GAC ACA CTG GTC TCC A-3Ј. The PCR product was then inserted into the Zero Blunt TOPO PCR Cloning vector (pCR-Blunt II; Invitrogen Life Technologies). Following confirmation of the nucleotide sequence, the PCR product was inserted into the EcoRI site of the pCAGGS (28) or pcDNA3.1 vector (Invitrogen Life Technologies) to generate pCAGGS-mIFN-and pcDNA3.1-mIFN-, respectively. For the N-terminal FLAG-tagged versions (pCAGGS-FLAG-mIFN-and pcDNA3.1-FLAG-mIFN-), 5Ј-ACC ATG GAC TAC AAA GAC GAT GAC GAC AAG CTC CTC CTG CTG TTG CCT CTG-3Ј were used as the forward primer. For the enrichment of transfected cells, the EcoRI fragment from pCR-Blunt II-mIFN-was inserted into pMACS K K .II (Miltenyi Biotec) and pIRES2-enhanced GFP (EGFP) bicitronic vector (BD Biosciences) to generate pMACS K K .IImIFN-and pIRES2-mIFN--EGFP, respectively. The expression plasmids for mouse IL-12 and IL-18, pCAGGS-IL-12, and pcDNA-mproIL-18-mICE have been described previously (19) .
For receptor expression, the following primers were used: mCRF2-4 (mIL-28R) sense, 5Ј-GAA CAG GAG AGT GGA GTG AA-3Ј; mCRF2-4 (mIL-28R) antisense, 5Ј-GAC TCT TCG CTG ATG ATG CT-3Ј; mCRF2-12 (mIL-10R␤) sense, 5Ј-ATG TGG CGG GCC GAC CGG TGG-3Ј; mCRF2-12 (mIL-10R␤) antisense, 5Ј-CCT GCC GTG TGC GGA AGC TGC-3Ј; GAPDH sense, 5Ј-GTA TCG TGG AAG GAC TCA TG-3Ј; and GAPDH antisense, 5Ј-AGT GGG TGT CGC GCT GTT GAA G-3Ј. PCR conditions for each set of primers included initial treatment at 94 o C for 2 min, followed by 35 cycles consisting of denaturation at 94 o C for 15 s, annealing at 57 o C for 30 s, followed by extension at 68 o C for 2 min. PCR products were analyzed on a 1% agarose gel.
Transfection, colony formation assay, Western blotting, and caspase-3/7 assay
Cells (5 ϫ 10 5 ) were transfected with plasmid DNA (1ϳ8 g) using Lipofectamine 2000 (Invitrogen Life Technologies). For the colony formation assay, cells were grown in regular medium for 2 days, followed by medium containing G418 geneticine (Invitrogen Life Technologies; 800 g/ml) for 14 days. G418-resistant colonies Ͼ3 mm in diameter were counted. For Western blotting, cells were lysed by sonication in radioimmunoprecipitation assay buffer (29) and then centrifuged for 10 min at 4°C. Each cell extract (10 g of protein) was assayed using the appropriate Abs and protein G-conjugated HRP (Amersham Biosciences). To detect caspase-3/7 activity, B16/F0 cells (1 ϫ 10 6 /60-mm plate) were transfected with pCAGGS-FLAG-IFN-(8 g) or pCAGGS empty plasmid (8 g), and cells (2 ϫ 10 4 /well of a 96-well plate) were plated 16 h following transfection. The Caspase-Glo 3/7 Assay system (Promega) was used according to the manufacturer's instructions 36 h after transfection. The background luminescence associated with cell culture and assay reagent (blank reaction) was subtracted from experimental values. Z-VAD-fmk (Promega) was used at 1 M as an inhibitor of IFN--mediated cell death. Means of triplicates were used to represent caspase-3/7 activity for the given cells. Each experiment was performed three times, with similar results.
Establishment of luciferase-expressing cells
Firefly (Photinus pyralis) luciferase cDNA from pGL3 basic (Promega) was inserted into the pMSCVpuro retroviral vector (Clonetech), generating pMSCV-luciferase. GP2-293 packaging cells (Clontech) were cotransfected with pMSCV-luciferase and pVSV-G (Clontech), a plasmid encoding the viral envelope glycoprotein (VSV-G) of the vesicular stomatitis virus, using Lipofectamine 2000 (Invitrogen Life Technologies). Supernatants from transfected GP2-293 were incubated with ϳ50% confluent B16/ F10 and Colon26 cells in the presence of Polybrene (8 g/ml final concentration; Sigma-Aldrich). Transduced cells were propagated in medium containing puromycin (Sigma-Aldrich) at 15 g/ml (luc-B16/F10 and luc-Colon26). 
Flow cytometry and magnetic bead selection
s.c. and i.v. tumor inoculation
Cells in exponential growth phase were harvested by trypsinization and washed twice in PBS before injection. For the s.c. injections, cells (1 ϫ 10 6 ) were injected into the abdominal s.c. space of mice. Tumor growth at the skin was monitored by measurement of the two maximum perpendicular tumor diameters. For immunization, mice were injected twice (day 0 and 6) s.c. with 1 ϫ 10 5 gamma-irradiated (80 Gy) cells that had been transiently transfected with plasmid DNA (2 g). On day 12, spleen cells were harvested for CTL activity. For the i.v. injections to the lungs, luc-B16/F10 cells (5 ϫ 10 4 in 0.2 ml of PBS) were injected into the tail vein of C57BL/6 mice. For tumor implantation to the liver, a midline incision was made on anesthetized mice, and 2 ϫ 10 5 luc-Colon26 cells in 0.2 ml of PBS was injected into the ileocolic vein of BALB/c mice. Each experiment was performed two to four times, with similar results.
In vivo bioluminescence imaging
In vivo tumor progression was examined using the noninvasive bioimaging system IVIS (Xenogen). Tumor-implanted mice were anesthetized with a mixture of ketamine and xylazine, and D-luciferin (potassium salt; Biosynth) was injected into the peritoneal cavity at 2 mg/body, immediately followed by measurement of the luciferase activity. EnduRen (0.5-1.0 mg/ body; Promega) was used to visualize Renilla (Renilla reniformis) luciferase expression from the pRL-TK vector (Promega). The imaging system consisted of a cooled, back-thinned charge-coupled device camera to capture both a visible light photograph of the animal taken with light emitting diodes and the luminescent image. After acquiring photographic images of each mouse, luminescent images were acquired with a 1-to 15-min exposure time (25, 26) . Images were obtained with a 25-cm field of view, a binning (resolution) factor of 8, 1/f stop, and an open filter. The resulting gray scale photographic and pseudocolor luminescent images were automatically superimposed by software to facilitate identification and location of any optical signal on the mouse. Optical images were displayed and analyzed using Igor (WaveMetrics) and IVIS Living Image (Xenoxgen) software packages. The signal from tumors was quantified as photons flux in units of photons/sec/cm 2 /steradian.
In vivo depletion of immune cells
Depleting anti-CD4 (clone GK1.5, rat IgG2b) and anti-CD8 (clone 2.43, rat IgG2b) mAbs were purified from the supernatant of hybridoma cells by passage through an affinity gel protein-G column (Amersham). To deplete host CD4 ϩ or CD8 ϩ T cells in vivo, animals received i.p. injection with purified mAbs (4 mg/kg) on days Ϫ1, 2, 5, 8, 12, and 14 of tumor inoculation. Anti-asialo GM1 Ab (100 g/body; WAKO) was used to deplete NK cells. Control rat IgG was purchased from Sigma-Aldrich.
Histological examination
Removed specimens were fixed with 10% paraformaldehyde and embedded in paraffin. Sections were stained with H&E.
Hydrodynamic injection of plasmid DNA
Twenty micrograms of pCAGGS-FLAG-IFN-and 20 g of pRL-TK were diluted in 1.6 ml of PBS (6.25% of body weight) (25) and injected into the tail or penile vein of BALB/c mice. The injection took no longer than 10 s, and the apnea period in mice ranged from 4 to 6 s. The Renilla luciferase-expressing pRL-TK vector was used to confirm liver targeting 24 h following hydrodynamic injection, and photons from Renilla luciferase were confirmed by IVIS (Xenogen).
Statistical analysis
Values of p were based on two-sided Student's t or Mann-Whitney U tests using the program Instat (GraphPad) for statistical evaluation. Differences between groups were considered significant if p Ͻ 0.05.
Results
Construction of the mouse IFN-expression vector and receptor expression in murine tumor cell lines
COS7 cells were transiently transduced with FLAG-tagged mouse IFN-cDNA and then subjected to Western blot analysis to examine the functional expression of cloned mouse IFN- (Fig. 1a) . A 23-kDa protein was identified by the anti-FLAG-M2 mAb in a transfection-dependent manner. Furthermore, mouse IFN-and EGFP were coexpressed in B16/F10 cells by a bicistronic expression vector, and MHC class I expression (H-2K b ) was analyzed using flow cytometry after gating the EGFP-positive population (Fig. 1b) . MHC class I expression was strongly enhanced following IFN-transduction but not by the mock transfection, and suggested that the transduced IFN-was functional. Interestingly, as with the case of IFN-␣ (6, 7), IFN-was able to induce cell surface expression of Fas in B16 cells (Fig. 1d) .
The expression of IFN-receptor in murine tumor cell lines was also examined by RT-PCR (Fig. 1e) . Although IL-10R␤ was expressed in all cell lines examined, IFN-R (IL-28R) was expressed at various levels. B16 melanoma and Colon26 colon cancer cells expressed IFN-R at higher levels. Thus, these cells could be potential targets of IFN-.
Overproduction of IFN-suppresses cell growth in vitro
B16/F0 and Colon26 cells were transduced with IFN-cDNA, and the generated G418-resistant cells were examined to determine the effect of IFN-on tumor growth. Immunoblot analysis did not show FLAG-tagged IFN-expression in cells derived from independent G418-resistant colonies (data not shown). The number of G418-resistant colonies following transfection was also evaluated (Fig. 2a) . Colony formation (Ͼ3 mm in diameter) was significantly inhibited by IFN-cDNA and its FLAG-tagged version in comparison to the mock transfection (Fig. 2, b and c) . Transient transfection of IFN-also induced retardation of cell growth in B16/F0 cells (Fig. 3a) . Furthermore, we investigated whether overexpression of IFN-induced apoptotic cell death (Fig. 3b) . IFN--transduced B16/F0 cells showed significantly increased caspase-3/7 activity 36 h following transfection compared with the mock transduction, and a general caspase inhibitor (Z-VAD-fmk) effectively blocked IFN--mediated apoptosis, demonstrating the specificity of the assay. Concomitant with increased caspase-3/7 activity, cell cycle regulator p21
Waf1/Cip1 induction and dephosphorylation of Rb (Ser 780 ) were also observed using Western blot analysis (Fig. 3c) . Thus, these results demonstrated that overexpression of IFN-induces cell cycle arrest and apoptotic cell death in target tumor cells.
Local expression of IFN-inhibits cutaneous tumor formation and pulmonary metastasis
In an effort to determine whether IFN-can inhibit in vivo tumor growth, Colon26 cells were transfected with IFN-cDNA and subsequently transplanted into the s.c. space of BALB/c mice. As shown in Fig. 4a, IFN-- IFN-and then injected into the tail vein of C57BL/6 mice. Pulmonary metastasis of luc-B16/F10 cells was monitored (Fig.  4, b-d) . Strikingly, IFN-treatment prevented pulmonary metastasis 14 days following tumor injection (Fig. 4, d-f) . Interestingly, histological examination of the lungs showed that IFN-treatment increased massive cellular infiltrates (Fig. 4, g  and h) , and suggested that immunological tumor destruction was also stimulated following IFN-treatment.
Implication of immune cells in IFN--mediated tumor suppression
In an effort to determine whether CD4 ϩ , CD8 ϩ T, or NK cells were involved in IFN--mediated tumor destruction, anti-CD4 ϩ , anti-CD8 ϩ , and anti-asialo GM1 Abs were i.p. injected before s.c. tumor challenge of B16/F10 cells. As shown in Fig. 5 , the in vivo depletion of NK cells facilitated progressive tumor growth following IFN-treatment compared with the control treatment ( p Ͻ 0.05). However, there was no difference in tumor growth in the CD4 ϩ and CD8 ϩ T cell-depleted group. Thus, these results suggested that NK cells are the predominant cells involved in the antitumor effect of IFN-, and that CD4 ϩ and CD8 ϩ T cells contribute less to IFN--induced tumor destruction.
Targeting of liver metastatic foci by hydrodynamic delivery of IFN-expression plasmid
Several studies, including those of our own group, have shown that systemic injection through the vein using a large volume of plasmid DNA solution (hydrodynamic gene delivery) can achieve efficient gene transfer into the liver. We therefore examined whether hydrodynamic gene delivery of IFN-could inhibit liver metastatic growth of Colon26 cells. Luciferase-transduced Colon26 cells (5 ϫ 10 5 ) were inoculated into the liver of BALB/c mice through the portal vein, and naked plasmid DNA of IFN-was injected i.v. into the penile vein of mice 3 days following posttumor inoculation. The therapeutic vector was coinjected with a pRL-TK Renilla-derived luciferase expression vector to monitor liver-selective gene delivery (Fig. 6a) . Tumor formation in the liver was measured by in vivo luminescent imaging (Fig. 6b) . Hydrodynamic injection of IFN-cDNA demonstrated significant retardation of tumor growth around day 9 posttumor injection compared with the mock plasmid injection. Tumor-derived photons with IFN-treatment were at a third of the level of the mock treatment at day 12 (Fig. 6c) . Mice receiving IFN-cDNA possessed moderately better survival (Fig. 6d) , and tumor-derived photons were not observed in 10 -20% of mice undergoing IFN--treatment on day 30. These mice were not free from the second tumor challenge at the s.c. site, but their tumor growth was retarded in comparison with that of naive mice, suggesting that IFN-may make a modest contribution to long-term antitumor immunity.
In an effort to address whether IFN-can support systemic CTL responses, tumor-killing activity was evaluated in vitro using spleen cells from C57BL/6 mice that were immunized by s.c. injection of irradiated IFN--transduced B16/F10 cells (Fig. 6e) was unable to induce sufficient tumor-killing activity. Thus, these results demonstrate that active immunization using IFN-can support systemic CTL-inducing activity.
Furthermore, we examined whether pulmonary metastasis of luc-B16/F10 cells could be inhibited by hydrodynamic delivery of IFN-cDNA (Fig. 6f) . Tumor-derived photons in the lungs could not be segregated between control and IFN-cDNA injections at day 15 after tumor implantation ( p ϭ 0.7). However, IFN--transduced luc-B16/F10 cells significantly suppressed the metastatic growth ( p Ͻ 0.05). These results therefore demonstrate that local delivery of IFN-is necessary for the control of metastatic tumor growth at target sites, and suggest that the IFN--meditated systemic CTL response is only weak.
IFN-increased the number of NK and NKT cells in the liver of mice
To address the role of IFN-expression in the liver, hepatic lymphocytes were isolated following hydrodynamic injection of IFNcDNA and analyzed by flow cytometry. As shown in Fig. 7a , the number of NK and NKT cells increased compared with the mock injection 2 days following IFN-cDNA injection: CD3 Ϫ NK1.1 ϩ cells increased from 10.9 to 26.9%, whereas CD3 ϩ NK1.1 ϩ cells increased from 1.0 to 11.0%. There was no significant increase in the total number of hepatic lymphocytes. Furthermore, IFN--exposed liver lymphocytes displayed significant killing activity against luc-Colon26 cells (Fig. 7b) . In fact, CD3
Ϫ DX5 ϩ cells substantially expressed IFN-R and IL-10R␤ (Fig. 7c) , and their IFN--exposure moderately enhanced killing of luc-Colon26 cells (Fig.  7d) . The NK cell depletion in vivo using anti-asialo GM1 Abs also demonstrates that functional NK cell activity against the luc-Colon26 tumor was elicited following IFN-cDNA treatment (Fig. 7,  d and e) . These results therefore demonstrated that forced expression of IFN-in the liver enhances the number of NK and NKT cells and augments their killing activity against tumors. This suggested that IFN-stimulates the innate immune system and may lead to the antitumor immunity. 
Discussion
We demonstrated the antitumor effect of mouse IFN-against murine tumor cells. The remarkable features presented in this study include the following: 1) IFN-induced cell cycle arrest and apoptotic cell death in vitro; 2) overexpression of IFN-inhibited s.c. and metastatic tumor formation in vivo; 3) NK cells were critical to IFN--mediated tumor growth inhibition in vivo; and 4) hydrodynamic delivery of IFN-cDNA achieved effective tumor targeting in liver metastatic foci.
Type I IFNs have been used for multiple clinical indications including malignant diseases, multiple sclerosis, and chronic hepatitis B and C (12) . Because human IL-28 and IL-29 can be induced following viral infection (14 -17) and treatment with IFN-␣ (33), their forced expression needed to be evaluated in terms of their antitumor activity (Figs. 2-4) . Although Dumoutier et al. (16) showed an anti-proliferative effect of IFN-in lymphoma cells, they did not demonstrate any substantial apoptotic effects. Melanoma B16 cells are less immunogenic and highly resistant to a variety of apoptotic stimuli such as anticancer agents if they are not manipulated (34 -36) . However, overexpression of IFN-in B16 cells induced cell surface MHC class I and Fas (CD95) and, moreover, markedly increased caspase-3/7 activity concomitant with cell cycle arrest (Fig. 3) . These changes could provide T cells with an enhanced ability to recognize and destroy target tumor cells. Nonetheless, because expression of the IL-28R in tumor cell lines was limited, local overexpression or intracellular expression of IFN-and its engagement may require the transduction of a signal to induce apoptosis. Given the decreased affinity for the receptor (14) and varied activity of different signal-transducing molecules (16) , the appropriate expression of the ligand therefore appears to yield a sufficient antitumor effect.
Substantial in vivo antitumor and antimetastatic activity was demonstrated by overproducing IFN- (Fig. 4) . Type I IFNs possess immunoregulatory functions as well as antiviral and antitumor activity. For example, IFN-␣ promotes phenotypic differentiation and increases MHC class I expression in normal and tumor cells, and serves as a critical link between innate and adaptive immunity (6, 7, 33) , in addition to being able to activate DCs, NK cells, and macrophages. In synergy with IL-18, IFN-␣ enhances IFN-␥ production in NK and T cells (37, 38) . IFN-␥ in turn can facilitate Ag presentation in DCs and macrophages, resulting in activation of adaptive immunity and elimination of tumor and virus-infected cells by CTLs. However, whereas active immunization using IFN-was able to induce CTLs (Fig. 6e) , our animal experiments in vivo using gene transfer of IFN-demonstrated only a modest CTL response. Our Ab-mediated immunodepletion experiments showed that NK cells were the predominant cells involved in the in vivo antitumor activity of IFN- (Fig. 5 ). Regarding NK cellmediated CTL induction, there is emerging data suggesting that induction of tumor-specific T cell memory is dependent upon NK cell-mediated tumor rejection (39, 40) . Our data therefore suggest that resident NK cells at the site may be critical targets for IFN-, and that IFN-may serve as a transducer inducing the innate immune response to adaptive immunity. This indirect pathway may explain why the CTL response by gene transfer of IFN-was still modest.
Furthermore, type I IFNs can reduce the amount of angiogenic growth factors in many tumor cells such as basic fibroblast growth factor (41, 42) , inhibiting tumor formation. Because the observed IFN-response was similar to the signal transduction pathway observed for type I IFNs (16), IFN-might possess potent antiangiogenic activity against tumor growth in vivo.
The intravascular delivery of naked plasmid DNA through the vein is an effective method for transferring DNA into the rodent liver. Systemic injection through a tail vein with a large volume of plasmid DNA solution can achieve effective gene transfer into the liver (23, 24) . This liver-targeted strategy possesses the following advantages: 1) the liver is the largest organ of the reticuloendothelial system and appropriate immunological responses could be introduced; and 2) plasmid DNA can potentially activate the TLR 9 that mediates innate immune reactions (43, 44) . The liver contains Ͼ70% of all tissue macrophages (Kupffer cells) and eliminates bacteria and foreign bodies from the circulation. The liver can respond rapidly to proinflammatory cytokines including IL-1␤ and TNF-␣, and hepatic sinusoidal lymphocytes also exert effects on NK cells (45) . Numerous studies in recent years have examined the potential of using DNA containing the CpG-motif, alone and in combination with other molecules, to boost the immunological response in a variety of disease settings including the treatment of cancer (46, 47) . Furthermore, DNA containing the CpG-motif can stimulate many DCs, leading to increased expression of MHC and costimulatory molecules, and the production of proinflammatory cytokines (48, 49) . With regard to liver targeting, our previous studies using a particle-mediated gene transfer method also demonstrated that primary hepatic immunization gave rise to a beneficial immune response against malaria, in which cellular and humoral immune responses were induced (21, 50, 51) . Thus, hepatic gene delivery of IFN-that activates NK/NKT cells could be useful in immunotherapy and may represent a reasonable approach for the management of liver metastasis.
Although hydrodynamic injection is a powerful gene delivery system for rodent animals, there are obvious clinical limitations associated with this method that relate to injection volume and rate. Volume and rate of injection are critical in the uptake of naked DNA plasmids, because a large fluid volume is needed (i.e., equivalent of the animal's blood volume) and it must be injected rapidly (23) . In fact, it has been reported that symptoms of transient cardiac failure are observed even in rodent animals during and immediately after injection (25) . Thus, hydrodynamic gene delivery cannot be translated to clinical settings until the adverse effects of this procedure are overcome.
The therapeutic options for patients with metastatic disease remain limited, and the majority of these patients will subsequently develop a local or systemic recurrence following the local treatment of liver metastases (52, 53) . A new treatment modality to control local disease and prevent systemic progression is required.
Interestingly, whereas 57% of mice with tumors subjected to hydrodynamic therapy with mouse IFN-␣ cDNA died within 24 h, only 13% of IFN-cDNA-treated mice died 24 h following treatment (data not shown). These data reflect the lower toxicity of IFN-. Overall, local immunotherapy still remains an attractive approach to control liver metastasis, and use of IFN-might prove a useful adjunctive strategy in the clinical treatment of human malignancies. Nonetheless, it remains of utmost importance to carefully examine the clinical data for evidence to support or refute the notion that use of IFN-enhances the regulation of human malignancy.
